Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$48.44M-22.6%-$74.92M+18.7%-$72.01M-333%-$17.36M+55.5%-$39.53M+57.8%
$62K+19.2%$59K+15.7%$64K+129%$45K+137%$52K+247%
$18M+18.3%$14.02M+48.9%$15.01M+87.7%$15.18M+83.1%$15.21M+92.1%
-$30.6M+16.1%-$40.88M-9.1%-$32.77M-162%-$37.67M+30.2%-$36.47M+33.2%
$38K+138%$100K+3,233%$42K-44.0%$88K-57.9%$16K-95.8%
-$11.51M-503%-$21.14M+66.0%$0+100%-$159.14M-76,042%$2.86M+842%
$11.07M+69.7%$13.68M-97.0%$5.89M+10,059%$3.43M-26.5%$6.52M-96.7%
-$31.05M-14.6%-$48.33M-114%-$24.37M-$193.38M-$27.09M-119%
-$30.64M+16.0%-$40.98M-9.3%-$32.81M-161%-$37.76M+30.3%-$36.48M+33.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does NewAmsterdam Pharma Company generate?
NewAmsterdam Pharma Company (NAMS) generated -$141.9M in operating cash flow over the trailing twelve months.
What is NewAmsterdam Pharma Company's free cash flow?
After $268.0K of capital expenditures, NewAmsterdam Pharma Company's free cash flow was -$142.2M over the trailing twelve months, down 1.0% year over year.
Where does NewAmsterdam Pharma Company's cash flow data come from?
Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.